Designing chiral libraries for drug discovery

Drug Discovery Today

Volumn 5, Issue 8, 2000, Pages 364-372

  Beroza, Paul ^a   Suto, Mark J ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIRALITY; DIASTEREOISOMER; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SYNTHESIS; LIBRARY; METHODOLOGY; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034256093     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01515-4     Document Type: Review

References (36)

1. Celis J.E. Proteomics. key technology in drug discovery Drug Discovery Today. 3:1998;193-195.
2. Schena M.et al. Microarrays. biotechnology's discovery platform for functional genomics Trends Biotechnol. 16:1998;301-306.
3. Frick L.W.et al. Cassette dosing. rapid in vivo assessment of pharmacokinetics Pharm. Sci. Technol. Today. 1:1998;12-18.
4. Watt A.P.et al. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discovery Today. 5:2000;17-24.
5. Persidis A. Proteomics. an ambitious drug development platform attempts to link gene sequence to expressed phenotype under various physiological states Nat. Biotechnol. 16:1998;393-394.
6. Rowe R.C., Roberts R.J. Artificial intelligence in pharmaceutical product formulation. neural computing and emerging technologies Pharm. Sci. Technol. Today. 1:1998;200-205.
7. Hemmila I., Webb S. Time-resolved fluorometry. an overview of the labels and core technologies for drug screening applications Drug Discovery Today. 2:1997;373-381.
8. Jones D.A., Fitzpatrick F.A. Genomics and the discovery of new drug targets. Curr. Opin. Chem. Biol. 3:1999;71-76.
9. Page M.J.et al. Proteomics: a major new technology for the drug discovery process. Drug Discovery Today. 4:1999;55-62.
10. Sun C.M. Recent advances in liquid-phase combinatorial chemistry. Comb. Chem. High Throughput Screen. 2:1999;299-318.
11. Kundu B.et al. Combinatorial chemistry. polymer supported synthesis of peptide and non-peptide libraries Prog. Drug Res. 53:1999;89-156.
12. Sundberg S.A. High-throughput and ultra-high-throughput screening. solution- and cell-based approaches Curr. Opin. Biotechnol. 11:2000;47-53.
13. Clark D.E., Pickett S.D. Computational methods for the prediction of 'drug-likeness'. Drug Discovery Today. 5:2000;49-58.
14. Tarbit M.H., Berman J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol. 2:1998;411-416.
15. Smith D.A., van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 3:1999;373-378.
16. Hann M.et al. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci. 39:1999;897-902.
17. Furka A., Bennett W.D. Combinatorial libraries by portioning and mixing. Comb. Chem. High Throughput Screen. 2:1999;105-122.
18. Blaney J.M., Martin E.J. Computational approaches for combinatorial library design and molecular diversity analysis. Curr. Opin. Chem. Biol. 1:1997;54-59.
19. Agrafiotis D.K.et al. Advances in diversity profiling and combinatorial series design. Mol. Diversity. 4:1998;1-22.
20. Kirkpatrick D.L.et al. Structure-based drug design. combinatorial chemistry and molecular modeling Comb. Chem. High Throughput Screen. 2:1999;211-221.
21. Spellmeyer D.C., Grootenhuis P.D.J. Recent developments in molecular diversity. computational approaches to combinatorial chemistry Annu. Rep. Med. Chem. 34:1999;287-296.
22. Stinson S.C. Chiral drug interactions. Chem. Eng. News. 77:1999;101-120.
23. Brossi A. Chiral drugs. synopsis Med. Res. Rev. 14:1994;665-691.
24. Winslow R. Birth of a blockbuster: Lipitor's unlikely route out of the lab. Wall Street Journal. January 24:2000;B1.
25. Merrifield R.B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:1963;2149-2154.
26. Scott A.K. Stereoisomers and drug toxicity. The value of single stereoisomer therapy. Drug Safety. 8:1993;149-159.
27. Fitos I.et al. Stereoselective allosteric binding interaction on human serum albumin between ibuprofen and lorazepam acetate. Chirality. 11:1999;115-120.
28. Lipinski C.A.et al. Experimental and computational appraches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;3-25.
29. Bush B.L., Sheridan R.P. PATTY. a programmable atom typer and language for automatic classification of atoms in molecular databases J. Chem. Inf. Comput. Sci. 33:1993;756-762.
30. Greene J.et al. Chemical functional queries for 3D database search. J. Chem. Inf. Comput. Sci. 34:1994;1297-1308.
31. Bures M.G. Recent techniques and applications in pharmacophore mapping. Charifson P.S. Practical Application of Computer-Aided Design. 1997;39-72 Marcel-Dekker.
32. McGregor M.J., Muskal S.M. Pharmacophore fingerprinting. 1. Application to QSAR and focused library design. J. Chem. Inf. Comput. Sci. 39:1999;569-574.
33. Pickett S.D.et al. Diversity profiling and design using 3D pharmacophores. pharmacophore-derived queries (PDQ) J. Chem. Inf. Comput. Sci. 36:1996;1214-1223.
34. Van Drie J.H., Nugent R.A. Addressing the challenges of combinatorial chemistry. 3D databases, pharmacophore recognition and beyond SAR and QSAR Env. Res. 9:1998;1-21.
35. Gillet V.J.et al. The effectiveness of reactant pools for generating structurally diverse combinatorial libraries. J. Chem. Inf. Comput. Sci. 37:1997;731-740.
36. Stanton R.V. et al. Combinatorial library design: maximizing model-fitting compounds within matrix synthesis constraints. J. Chem. Inf. Comput. Sci. 40:2000;701-705.